| 臺大學術典藏 |
2022-06-27T07:01:34Z |
Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC Patients treated with first-line intercalated erlotinib and chemotherapy
|
Mok T.; Wu Y.-L.; Lee J.S.; CHONG-JEN YU; Sriuranpong V.; Sandoval-Tan J.; Ladrera G.; Thongprasert S.; Srimuninnimit V.; Liao M.; Zhu Y.; Zhou C.; Fuerte F.; Margono B.; Wen W.; Tsai J.; Truman M.; Klughammer B.; Shames D.S.; Wu L. |
| 臺大學術典藏 |
2022-06-27T07:00:18Z |
Tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine/platinum in the first-line treatment of advanced non-small-cell lung cancer
|
Mok T.; Ladrera G.; Srimuninnimit V.; Sriuranpong V.; CHONG-JEN YU; Thongprasert S.; Sandoval-Tan J.; Lee J.S.; Fuerte F.; Shames D.S.; Klughammer B.; Truman M.; Perez-Moreno P.; Wu Y.-L. |
| 臺大學術典藏 |
2020-12-02T02:34:19Z |
A multicentre phase II gene expression profiling study of putative relationships between tumour biomarkers and clinical response with erlotinib in non-small-cell lung cancer
|
Tan E.-H.;Ramlau R.;Pluzanska A.;Kuo H.-P.;Reck M.;Milanowski J.;Au J.S.-K.;Felip E.;Pan-Chyr Yang;Damyanov D.;Orlov S.;Akimov M.;Delmar P.;Essioux L.;Hillenbach C.;Klughammer B.;Mcloughlin P.;Baselga J.; Tan E.-H.; Ramlau R.; Pluzanska A.; Kuo H.-P.; Reck M.; Milanowski J.; Au J.S.-K.; Felip E.; PAN-CHYR YANG; Damyanov D.; Orlov S.; Akimov M.; Delmar P.; Essioux L.; Hillenbach C.; Klughammer B.; McLoughlin P.; Baselga J. |
| 臺大學術典藏 |
2020-08-12T06:34:46Z |
Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC Patients treated with first-line intercalated erlotinib and chemotherapy
|
Mok T.;Wu Y.-L.;Lee J.S.;Chong-Jen Yu;Sriuranpong V.;Sandoval-Tan J.;Ladrera G.;Thongprasert S.;Srimuninnimit V.;Liao M.;Zhu Y.;Zhou C.;Fuerte F.;Margono B.;Wen W.;Tsai J.;Truman M.;Klughammer B.;Shames D.S.;Wu L.; Mok T.; Wu Y.-L.; Lee J.S.; CHONG-JEN YU; Sriuranpong V.; Sandoval-Tan J.; Ladrera G.; Thongprasert S.; Srimuninnimit V.; Liao M.; Zhu Y.; Zhou C.; Fuerte F.; Margono B.; Wen W.; Tsai J.; Truman M.; Klughammer B.; Shames D.S.; Wu L. |
| 臺大學術典藏 |
2020-05-26T09:27:00Z |
Biomarker analyses from a randomized, placebo-controlled, phase IIIb trial comparing bevacizumab with or without erlotinib as maintenance therapy for the treatment of Advanced Non-Small-Cell Lung Cancer (ATLAS)
|
Kabbinavar F;Fehrenbacher L;Hainsworth J;Kasubhai S;Kressel B;Marsland T;Patel T;Rubin M;White L;Chih-Hsin Yang;Klughammer B;Colburn D;Miller V;Johnson B.E.; Kabbinavar F; Fehrenbacher L; Hainsworth J; Kasubhai S; Kressel B; Marsland T; Patel T; Rubin M; White L; CHIH-HSIN YANG; Klughammer B; Colburn D; Miller V; Johnson B.E. |
| 臺大學術典藏 |
2020-04-10T12:51:07Z |
Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: The phase II RACHEL study
|
Van Cutsem E.; Li C.-P.; Nowara E.; Aprile G.; Moore M.; Federowicz I.; Van Laethem J.-L.; Chiun Hsu; Tham C.K.; Stemmer S.M.; Lipp R.; Zeaiter A.; Fittipaldo A.; Csutor Z.; Klughammer B.; Meng X.; Ciuleanu T. |
| 臺大學術典藏 |
2014 |
Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: The phase II RACHEL study
|
Ciuleanu T.; Klughammer B.; Meng X.; Csutor Z.; Fittipaldo A.; Zeaiter A.; Lipp R.; Stemmer S.M.; CHIUN HSU; Tham C.K.; Van Cutsem E.; Li C.-P.; Nowara E.; Aprile G.; Moore M.; Federowicz I.; Van Laethem J.-L. |
| 國立臺灣大學 |
2012 |
BIOMARKER ANALYSES AND OVERALL SURVIVAL (OS) FROM THE RANDOMIZED, PLACEBO-CONTROLLED, PHASE 3, FASTACT-2 STUDY OF INTERCALATED ERLOTINIB WITH FIRST-LINE CHEMOTHERAPY IN ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC)
|
Mok, T. S. K.; Lee, J. S.; Zhang, L.; Yu, C.; Thongprasert, S.; Ladrera, G. E. I.; Srimuninnimit, V.; Truman, M. I.; Klughammer, B.; Wu, Y. |
